multiple-sclerosis

Documents about multiple-sclerosis

• Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis#869729ClinicalTrials.gov
• RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS#877671ClinicalTrials.gov
• Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis#911875ClinicalTrials.gov
• Aspirin for Treatment of Multiple Sclerosis-Related Fatigue#835663ClinicalTrials.gov
• Task-oriented Training Intervention for Multiple Sclerosis Patients.#835849ClinicalTrials.gov
• Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis#836228ClinicalTrials.gov
• Thalamic Nuclei Volumes in Multiple Sclerosis#837628ClinicalTrials.gov
• Auditory Functions in Patients With Multiple Sclerosis#845985ClinicalTrials.gov
• T Cell Profiling in Patients With Multiple Sclerosis#866292ClinicalTrials.gov
• Trunk Restraint in Multiple Sclerosis#878656ClinicalTrials.gov
• Emotions in Multiple Sclerosis#892122ClinicalTrials.gov
• Coping and Adjusting to Living With Multiple Sclerosis#905959ClinicalTrials.gov
• Demographics, Clinical and Paraclinical Characteristics of Multiple Sclerosis in Egypt#916082ClinicalTrials.gov
• A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis#882183ClinicalTrials.gov
• Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients#851272ClinicalTrials.gov
• Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)#877312ClinicalTrials.gov
• The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients#896282ClinicalTrials.gov
• fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls#899237ClinicalTrials.gov
• MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)#835995ClinicalTrials.gov
• Impact of Vitamin A on Multiple Sclerosis (MS)#863761ClinicalTrials.gov
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis#894954ClinicalTrials.gov
• Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis#849820ClinicalTrials.gov
• Time Restricted Eating Outcomes in Multiple Sclerosis#143738ClinicalTrials.gov
• Efficacy of PoNS in Reducing Symptoms of Multiple Sclerosis#828013ClinicalTrials.gov
• Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants#837693ClinicalTrials.gov
• Multiple Sclerosis Produces Cardiovascular Subclinical Dysfunction#844843ClinicalTrials.gov
• Trunk Control and Disability in Persons With Multiple Sclerosis#856517ClinicalTrials.gov
• Early Cognitive Impairment in Multiple Sclerosis#864311ClinicalTrials.gov
• Histaminergic Basis of Fatigue in Multiple Sclerosis#866068ClinicalTrials.gov
• Physical Telerehabilitation in Veterans With Multiple Sclerosis#875981ClinicalTrials.gov
• LoveYourBrain Yoga for Multiple Sclerosis#878039ClinicalTrials.gov
• tDCS for the Management of Multiple Sclerosis Related Fatigue#879700ClinicalTrials.gov
• Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis#882578ClinicalTrials.gov
• Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses#883943ClinicalTrials.gov
• Study of Oral Fampridine-SR in Multiple Sclerosis#887153ClinicalTrials.gov
• Multiple Sclerosis Intimacy and Sexuality Questionnaire#907241ClinicalTrials.gov
• Relıabılıty and valıdıty of the Two-minute Test wıth Multiple Sclerosis#913296ClinicalTrials.gov
• The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative#968647ClinicalTrials.gov
• Dubousset Functional Test: an Investigation of Its Validity and Reliability in Individuals with Multiple Sclerosis#868041ClinicalTrials.gov
• Kinesiotape on Balance in With Multiple Sclerosis#868845ClinicalTrials.gov
• Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis#863079ClinicalTrials.gov
• Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients#911555ClinicalTrials.gov
• Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).#873704ClinicalTrials.gov
• An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis#851353ClinicalTrials.gov
• Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)#872232ClinicalTrials.gov
• Efficacy and Safety of GTR in Comparison to Copaxone®#877549ClinicalTrials.gov
• Cell therapy in multiple sclerosis: An overview#147484HAL (France)
• Effect of MD1003 in Spinal Progressive Multiple Sclerosis#806980ClinicalTrials.gov
• Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder#813999ClinicalTrials.gov
• Defining an Immunological Signature Related to Lesion Location in Multiple Sclerosis#840296ClinicalTrials.gov